Home › Funds › Schonfeld Strategic Advisors LLC › INBX

Schonfeld Strategic Advisors LLC position in INBX

INHIBRX BIOSCIENCES INC COM · Health Care

Schonfeld Strategic Advisors LLC reported holding 697,586 shares of INBX (INHIBRX BIOSCIENCES INC COM) in its Q2 2026 13F filing — a position valued at US$66.1M, representing 0.43% of its reported portfolio and ranking #25 among its reported holdings. Schonfeld Strategic Advisors LLC has disclosed INBX holdings in 10 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)697.59K sh
Reported value held$66.10M
Portfolio Weight0.43%
First reportedQ4 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Schonfeld Strategic Advisors LLC's INBX position evolved

Schonfeld Strategic Advisors LLC first disclosed a stake in INBX in Q4 2023 at 89,330 shares (US$3.4M). The position peaked in Q2 2026 at 697,586 shares, worth US$66.1M. Across 10 filings, Schonfeld Strategic Advisors LLC increased the stake 5 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 697,586 shares valued at US$66.1M — an increase of 442,759 shares quarter over quarter.. Notable position changes include a 90% increase in Q3 2024 (shares fell 2% over the following quarter), a 120% increase in Q4 2025 (shares fell 15% over the following quarter), a 174% increase in Q2 2026 (shares rose 6% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 89.33K $3.39M New
Q2 2024 75.98K $1.08M New
Q3 2024 144.18K $2.26M Add
Q4 2024 144.18K $2.22M Hold
Q1 2025 144.18K $2.02M Hold
Q2 2025 154.79K $2.21M Add
Q3 2025 97.38K $3.28M Reduce
Q4 2025 214.72K $16.96M Add
Q1 2026 254.83K $17.13M Add
Q2 2026 697.59K $66.10M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About INBX and 13F data

INBX (INHIBRX BIOSCIENCES INC COM) is a Health Care company. 43 other funds we track also report a position in INBX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$123.0M), Sanofi (US$109.7M), PFM Health Sciences, LP (US$29.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding INBX

All INBX fund holders →

FAQ

How long has Schonfeld Strategic Advisors LLC held INBX?

Schonfeld Strategic Advisors LLC has disclosed INBX holdings in 10 of the last 11 reported quarters, going back to Q4 2023.

What is Schonfeld Strategic Advisors LLC's current position in INBX?

As of Q2 2026, Schonfeld Strategic Advisors LLC holds 697.59K shares of INBX (INHIBRX BIOSCIENCES INC COM), valued at $66.10M, representing 0.43% of its reported portfolio and ranking #25.

Has Schonfeld Strategic Advisors LLC been buying or selling INBX?

In the latest 13F filing (Q2 2026), Schonfeld Strategic Advisors LLC increased its position in INBX. The position peaked in Q2 2026 at 697.59K shares.

Which other funds hold INBX?

Other major institutional holders of INBX include PERCEPTIVE ADVISORS LLC, Sanofi, PFM Health Sciences, LP, among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.